StockWireNews

Could Low Float (NMTC) Be Ready For A Massive Breakout After Their CEO Was Interview On The Fox Business Network?

November 21st

Greetings Readers,

It's a short week with the upcoming holiday, so let's jump right into it.

Monday's alert came out hot on breaking news to hit a new 2+ week high.

Surging to $1.25 after closing this past Friday at $1.06, it moved approximately 17% and got the week kicked off just right.

But like I said, it's a short week and it's time to get another Nasdaq past champ on radar.

And when I brought this profile to you previously in 2022, all it did was go on a short term tear of approximately 50+% and a $1.00+.

Yup. It was a big boy. But let me ask something important...

What do you know about the future $20.1Bn neurostimulation devices market?

If it's not much, don't worry. All you need to soak in is the sheer size of this potential market by 2030 and let me fill in the details.

I've uncovered a company that is forwarding their game-changing tech to become an industry disruptor, but for now has flown well under Wall Street's radar.

But after the CEO was interviewed on the Fox Business Network on Monday, along with this profile's low float and explosive chart history, it needs to be back on your radar ASAP.

Ready for the goods? Here it is:

*NeuroOne Medical Technologies Corporation (NMTC)*

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders that may improve patient outcomes and reduce procedural costs.

And right now, NMTC has 5 potential catalysts to immerse yourself in:

No. 1 - Low Float Volatility Could Grab Hold

No. 2 - CEO Dave Rosa Interviewed On Fox Business Network (Added Company Exposure)

No. 3 - FDA 510(k) Clearance Is Most Exciting And Important Accomplishment To Date

No. 4 - Accelerated Milestone Payment Accomplishes Multiple Objectives (Huge News)

No. 5 - Explosive Chart History Filled With Strong Short Term Moves

But more on those in a second...

Brain Monitoring - Understanding What Allows Us To Sense, Move, Think And Feel. (1)

Neurons

86 BILLION NEURONS

Neurons communicate through electrical and chemical signals. The specific properties of the neurons composing a brain area and their connections with neurons in other brain areas, define the function of a brain area (e.g. language, vision, movement).

Monitoring Neural Activity

THEY CAN RECORD ELECTRICAL SIGNALS

There are different ways to record and monitor neural activity. Their solution is to provide electrodes that are placed on top of or within the brain and capture the activity of a group of neurons located underneath/around each contact. The signals recorded are called intracranial electroencephalogram (iEEG) or electrocorticography (ECoG) signals. The shape, amplitude and frequency of these electrical signals provide a readout of the activity of that brain area.

Monitoring Neurological Disorders

Neurological diseases may be associated with disturbances in neural activity and connectivity between brain areas. The changes in the shape, amplitude and frequency of recorded electrical signals may be used to identify areas with altered activity.

Epilepsy

Epilepsy is the disease associated with spontaneously recurring seizures. A seizure is a sudden, uncontrolled electrical disturbance in the brain. It can cause changes in behavior, movements or feelings, and in levels of consciousness. There are different types of seizures and their characterization and classification helps guide the treatment.

There are more than twenty seven FDA-approved drugs for the treatment of seizures. However, in ~1/3 of the patient's medication fails to control their seizures. These patients are candidates for surgical options.

Evo® Cortical Electrode

Cortical or subdural electrodes are used in electrocorticography (ECoG) or intracranial electroencephalography (iEEG) surgeries to monitor, record and stimulate the surface of the brain for up to 30 days. The company's Evo cortical electrode portfolio consists of various contact configurations of strip and grid electrodes. (Rx only)

The Evo Advantage (2)

Decreased Immunological Response - The Evo Electrode is over 7 times thinner than a silicone electrode. The flexibility and reduced volume should reduce pain and edema.

The Evo’s polyimide substrate has properties like increased flexibility, reduced volume, and decreased immunological response, which should reduce signal artifacts.

Single Tail Design - The single thin tail design allows the implanted electrode tail to be tunneled through one incision which should reduce infection risk and procedure time.

Reduced Cable Management - A disposable cable assembly is sent with each Evo Electrode as an electrode kit, removing the need to source the correct cables for each electrode being used in surgery. Also, hospital resources are freed from the management of sterilizing and storing individual electrode cable assemblies.

How NeuroOne's Thin Film Electrode Technology is Different

In comparison to currently available technologies, our electrodes are manufactured with polyimide thin film. Our electrodes are designed to reduce trauma to the brain by allowing a less invasive implant due to the flexibility, thinness and reduced weight of the electrode.

Furthermore, the potential to significantly increase the resolution of brain recordings may enable the usage of powerful computing techniques, such as machine learning and artificial intelligence.

Caution: US Federal law restricts this device to sell by or on the order of a physician

Two FDA-Cleared Devices and Counting (3)

Are you beginning to understand that NeuroOne is not just “another” MedTech company? In fact, their Evo Cortical and sEEG Electrodes are both FDA approved!

What they are doing right now has incredible implications for the future of the medical industry.

So much so that the technologies below could be commonplace and in wide use across the globe.

Read more from the company website here.

And as I mentioned previously, NMTC has 5 must-see potential catalysts right now:

-----

No. 1 NMTC Potential Catalyst - Low Float Volatility Could Grab Hold

Volatility could be the name of the game for this one.

According to Yahoo Finance, NMTC only has just above 12.34Mn shares in its float.

With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.

-----

No. 2 NMTC Potential Catalyst - CEO Dave Rosa Interviewed On Fox Business Network (Added Company Exposure)

NeuroOne® CEO Dave Rosa Featured on Fox Business Network's 'Mornings with Maria'

EDEN PRAIRIE, Minn., Nov. 21, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces an appearance by Chief Executive Officer Dave Rosa on Fox Business Network's Mornings with Maria earlier today. The segment, which aired live at 8:45 a.m. ET, can be viewed online at on-air-mornings-with-maria.

In conversation with veteran business journalist and anchor Maria Bartiromo, Mr. Rosa discussed NeuroOne's mission in advancing a new era in neuroscience with its game-changing thin film electrode technology developed in collaboration with Mayo Clinic. NeuroOne recently announced a milestone achievement for its Evo® sEEG Electrode, receiving FDA 510(k) clearance to market the system for temporary (less than 30 day) use. Upcoming business catalysts include the market launch of the Evo® sEEG diagnostic electrode line* and progress on a new RF ablation system in development, the Company's first therapeutic electrode technology.

Mornings with Maria on Fox Business Network (6-9 AM/ET) is the number one pre-market business news program on cable. Maria Bartiromo and her guests discuss news stories -- domestic and international -- and other topics that are expected to impact the economy and markets that day.

Read the full article here.

-----

No. 3 NMTC Potential Catalyst - FDA 510(k) Clearance Is Most Exciting And Important Accomplishment To Date

NeuroOne® Receives FDA 510(k) Clearance to Market its Evo® sEEG System for Less than 30 Day Use

Company focused on manufacturing ramp for commercialization in partnership with Zimmer Biomet

EDEN PRAIRIE, Minn., Oct. 25, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Evo sEEG Electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.

...

"I am extremely proud of the entire NeuroOne team and their relentless pursuit of this clearance. Despite the challenges we faced, our team remained focused and persistent in driving this successful conclusion. This is clearly our most exciting and important accomplishment to date. We are now able to advance our commercialization efforts in partnership with Zimmer Biomet, our distribution and development partner. We look forward to continuing to execute our strategic plan, which next up includes our RF ablation system, the Company's first therapeutic electrode technology," said Dave Rosa, CEO of NeuroOne.

The Evo sEEG System represents the Company's second FDA 510(k) cleared product. NeuroOne now provides a full line of electrode technology to address an estimated worldwide market of $100Mn for patients requiring diagnostic brain mapping procedures. As opposed to cortical electrodes, sEEG electrodes provide a similar function at the subsurface level of the brain by using a much less invasive process that does not require removal of the top portion of the patient's skull. sEEG electrodes are the predominant technology used in these procedures due to their less invasive placement and subsurface location.

The Company's Evo Cortical and sEEG Electrodes are a portfolio of hi-definition thin film electrodes. Potential advantages include increased signal clarity and reduced noise; better tactile feedback during insertion into brain tissue; and faster order fulfillment due to an automated manufacturing process.

As previously reported, NeuroOne is also advancing a pipeline of therapeutic electrode technologies for brain tissue ablation and chronic stimulation use for DBS (deep brain stimulation) and spinal cord stimulation for chronic back pain. These therapeutic electrode technologies represent addressable markets valued between $500Mn and $6Bn.

Read the full article here.

-----

No. 4 NMTC Potential Catalyst - Accelerated Milestone Payment Accomplishes Multiple Objectives (Huge News)

NeuroOne® Announces $3.5Mn Accelerated Milestone Payment from Zimmer Biomet for Evo® sEEG Electrode

Amendment provides Zimmer Biomet with 350k warrants with exercise price of $3.00 per share

EDEN PRAIRIE, Minn., Aug. 3, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the Company entered into an amendment to its Exclusive Development and Distribution Agreement with Zimmer Biomet, Inc. ("Zimmer") that will provide the Company with a $3.5Mn accelerated payment within 10 business days which relates to certain milestone payments. In addition, Zimmer Biomet will receive a Warrant to purchase 350k shares of the Company's common st-ock, with an exercise price of $3.00 per share.

Dave Rosa, Chief Executive Officer of NeuroOne, states, "I want to thank Zimmer for all their support to date and their confidence in our business, technology and future endeavors. This agreement accomplishes multiple objectives for NeuroOne, most importantly by providing additional capital to our balance sheet in the short-term without the need for a highly dilutive financing, and further reinforcing our ongoing partnership with Zimmer."

Brian Hatcher, President of the Trauma, CMFT, Foot and Ankle Division of Zimmer said, "We look forward to continuing the relationship with NeuroOne as we advance our mission to alleviate pain and improve the quality of life for people around the world." Under the Exclusive Development and Distribution Agreement signed by both parties in July 2020, Zimmer Biomet has exclusive global distribution rights to distribute the Company's Cortical and sEEG diagnostic electrode technology.

Read the full article here.

-----

No. 5 NMTC Potential Catalyst - Explosive Chart History Filled With Strong Short Term Moves

NMTC has a chart filled with several breakout runs. Check it out:

Here's a few examples to soak in:

#1. From a $1.70 low on 1/31, NMTC once again went running to a high of $3.18 on 2/11 for a move of 87%.

#2. NMTC leaped from a low of $1.1703 on 8/2 to a high of $1.95 on 8/3 for a blast of 66%.

#3. From 8/29's low of $1.72, NMTC cruised to a high of $2.95 on 8/31 for a run of 71%.

Like I said, explosive.

-----

NMTC Recap: 5 Potential Breakout Catalysts To Know Immediately

No. 1 - Low Float Volatility Could Grab Hold

No. 2 - CEO Dave Rosa Interviewed On Fox Business Network (Added Company Exposure)

No. 3 - FDA 510(k) Clearance Is Most Exciting And Important Accomplishment To Date

No. 4 - Accelerated Milestone Payment Accomplishes Multiple Objectives (Huge News)

No. 5 - Explosive Chart History Filled With Strong Short Term Moves

-----

Coverage is officially reinitiated on NMTC. When time permits, do this:

Get NMTC on your radar now.

Sincerely,

Kai Parker

StockWireNews

Source 1
Source 2
Source 3

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)